Nurix Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NRIX research report →
Range $28 – $45
Price Chart
About the company
Nurix Therapeutics, Inc. , a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications.
- CEO
- Arthur T. Sands
- IPO
- 2020
- Employees
- 317
- HQ
- Brisbane, CA, US
Get TickerSpark's AI analysis on NRIX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.37B
- P/E
- -6.63
- PEG
- 0.25
- P/S
- 64.59
- P/B
- 6.31
- EV/EBITDA
- -7.40
- Div Yield
- 0.00%
- Gross Margin
- -165.51%
- Op Margin
- -982.37%
- Net Margin
- -928.44%
- ROE
- -76.09%
- ROIC
- -77.32%
Latest fiscal year · YoY change
- Revenue
- $83.98M+54.0%
- Gross Profit
- $65.12M+139.0%
- Op Income
- $-285,666,000
- Net Income
- $-264,457,000-36.6%
- EPS
- $-3.05-5.9%
- OCF Growth
- -44.5%
- FCF Growth
- -44.9%
- 52W High
- $28.23
- 52W Low
- $8.20
- 50D MA
- $25.29
- 200D MA
- $19.59
- Beta
- 1.80
- RSI (14)
- 34
- Avg Volume
- 1.26M
No earnings-call transcripts are available for NRIX yet.
- Free Float
- 94.7%
- Shares Outstanding
- 103.78M
- Float Shares
- 98.26M
of shares held by institutions
198 13F filers
Buy/sell ratio 0.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 8.77M | ▼ 155.29K |
| Vestal Point Capital, LP | 8.05M | ▲ 1.55M |
| Deep Track Capital, LP | 7.74M | ▲ 1.39M |
| Rubric Capital Management LP | 7.23M | ▲ 4.75M |
| Vanguard Group Inc | 5.95M | ▲ 1.46M |
| Fmr LLC | 5.49M | ▼ 56.06K |
| Price T Rowe Associates Inc | 5.44M | ▲ 2.15M |
| Morgan Stanley | 4.76M | ▼ 169.51K |
| State Street Corp | 4.68M | ▼ 463.95K |
| Baker Bros. Advisors LP | 4.66M | 0 |
| Vanguard Capital Management LLC | 4.50M | ▲ 68.42K |
| Perceptive Advisors LLC | 4.32M | ▲ 609.54K |
Held by 248 ETFs
Biggest fund positions in NRIX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 2, 26 | Ring Christine | other | 5,786 |
| Oct 2, 26 | Ring Christine | other | 5,786 |
| Oct 2, 26 | Ring Christine | sell | 5,786 |
| Sep 2, 26 | Ring Christine | other | 5,787 |
| Sep 2, 26 | Ring Christine | other | 5,787 |
| Sep 2, 26 | Ring Christine | sell | 5,387 |
| Sep 2, 26 | Ring Christine | sell | 400 |
| Sep 1, 26 | Hansen Gwenn | other | 1,452 |
| Sep 1, 26 | Hansen Gwenn | sell | 1,452 |
| Sep 1, 26 | Hansen Gwenn | other | 1,452 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NRIX coverage
Recent articles, reports, and earnings notes.
No research on NRIX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NRIX report →Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences
globenewswire.com · Oct 5
Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer
globenewswire.com · Sep 29
842,089 Shares in Nurix Therapeutics, Inc. $NRIX Bought by Bank of America Corp DE
defenseworld.net · Sep 25
Nurix Therapeutics, Inc. (NRIX) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript
seekingalpha.com · Sep 17
Nurix Therapeutics, Inc. (NRIX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
seekingalpha.com · Sep 16
Here's Why You Should Add NRIX Stock to Your Portfolio Now
zacks.com · Sep 10
Nurix Therapeutics, Inc. (NRIX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
seekingalpha.com · Sep 10
Nurix Therapeutics (NRIX) Upgraded to Buy: Here's Why
zacks.com · Sep 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.